For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Effects of Telmisartan on Arterial Stiffness Assessed by the Cardio-Ankle Vascular Index in Hypertensive PatientsKinouchi K.a · Ichihara A.b · Sakoda M.a · Kurauchi-Mito A.a · Murohashi-Bokuda K.a · Itoh H.a
Departments of aEndocrinology, Metabolism, and Nephrology, and bEndocrinology and Anti-Aging Medicine and Internal Medicine, Keio University School of Medicine, Tokyo, Japan Corresponding Author
Atsuhiro Ichihara, MD, PhD, FAHA
Endocrinology and Anti-Aging Medicine, Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582 (Japan)
Tel. +81 3 5363 3796, Fax +81 3 3359 2745, E-Mail email@example.com
Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.
© 2010 S. Karger AG, Basel